RE:RE:RE:RE:RE:RE:RE:what am i missingNoMoreTax I do tend to agree with you and have posted before describing it in terms of the Peter Principle. We all get to a stage in business where our successes in the past are no longer the skills needed for the future.
I believe Don is a "good guy" but I do take shots at him when he doesn't seem to live up to promises. It's always better to under promise and over deliver.
On the closing deals side I will certainly give Don credit for closing Hepalink and to me this is a big deal because it dramatically provides a strategy to become a downstream pharma and it provides access to a huge market and a market in which CVD and diabetes melletus growing exponentially. Also, Hepalink has purchased a USA based pharma and will probably continue to expand via acquisitions. With Hepalink as an insider at RVX and having a seat on the board and a team of scientists which have tested rvx-208 (apabetalone) every way to Sunday you can bet they are very sure rvx-208 will be a blockbuster. Hence, being insiders they may be the first to take a shot at a buy out of RVX or perhaps just apabetalone.
Also the science has attracted big money over the years in terms of Eastern and NGN. They have their scientists to assess rvx-208.
BETonMACE has a highly respected scientific steering committee and RVX has attracted excellent scientists. Agian, another sign that is a serious contender and it is based on break through science. It was either Crick or Watt (double helix discoverers and Nobel Laureates) that got Dr Wong tuned in to epigenetics.
With their peer reviewed article in the respected journal Athersclerosis you can see this is a company with very significant potential.
I and I think others have some belief that the big pharmas are not in there yet is because they have had discussions with Don and they balking at the price because Don knows he has a blockbuster and with 1400 other epigenetic compounds in the RVX posrfolio there may be more drugs developed as per the orphan trials, Alzhemiers, etc, etc.
So I am critical of Don because I don't think he is tight enough when he makes big claims but doesn't back them up with concrete timelines. I'm also critical of RVX because they have a huge story (actually many stories of success) to tell and they have not got a clue of how to get the message out and worse they see no reason to get the message out.
Could a new CEO cut a deal. I think a new CEO could have a short term positive hit on the share price but I'm not sure it would be good for the RVX culture. Apabetalone will be the deal maker.
Anyway, your thought got me rambling. I'm excited and frustrated.
GLTA
Toinv